Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the researchers analyzed skin samples from Dun Mongolian horses to uncover molecular pathways linked to the "Bider" marking, identifying differential gene expression and several pigment-related signaling pathways that may play key roles in its formation.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This study observed that JAK inhibitors were safe and effective for patients with moderate-to-severe alopecia areata and comorbid latent hepatitis B or stable tuberculosis, with careful monitoring and selective prophylaxis.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

In this study, intradermal injection of botulinum toxin type A significantly increased hair count and improved physician-assessed hair condition in men with male pattern baldness after 24 weeks, with no serious adverse events reported beyond temporary local pain and redness.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This study developed dissolving microneedles using specific polymers for transdermal delivery of rizatriptan benzoate, demonstrating improved drug skin penetration and significant alleviation of migraine symptoms in vivo compared to passive diffusion, suggesting potential advantages over conventional treatment methods for acute migraine.

In this research letter from the British Journal of Dermatology, the authors explore the use of topical tofacitinib to treat alopecia areata affecting facial hair, but specific results are not reported in the abstract.

This study developed the TLMG hydrogel, a seamless in situ biointerface platform, demonstrating robust adhesion, high conductivity, and therapeutic effects for intelligent wound management in complex animal models and human tests, indicating its promise for integrated bioelectronic medicine.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

In this study, tofacitinib and baricitinib showed similar effectiveness and safety in treating alopecia areata, but baricitinib had a higher rate of early responders. Baseline hair loss severity was identified as the only independent predictor of treatment response.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This case report describes a woman with trichotillomania who experienced marked improvement and hair regrowth after off-label onabotulinumtoxinA treatment.

This study found that terbinafine prevented the invasion of keratin by Trichophyton mentagrophytes in experimental models replicating human dermatomycoses.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This review discusses various cancer prevention strategies, summarizing established successes like tamoxifen for breast cancer and mixed outcomes of preventive trials like finasteride for prostate cancer, and reports no new results.

This study observed that Aconiti Ciliare Tuber extract may promote hair growth in mice by activating the Wnt/β-catenin signaling pathway.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

Baricitinib is a safe and effective treatment for severe alopecia areata.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

In this study, researchers observed that shikonin promotes wound healing in a mouse burn model by enhancing skin cell proliferation and fibroblast activity through the PI3K/AKT signaling pathway, suggesting its potential as a therapeutic treatment for skin injuries.